Organon PE ratio OGN

Share price divided by earnings per share over the last twelve months, since 2022.

Today, Oct 23, 2026: 17.9×
5-year median: 5.9×
Against its 5-year history: 97th; percentile: 0 is its lowest day, 100 its highest
5-year range: 2.5× to 18.7×
Peer median: 31.5×

Organon's PE ratio is 17.9× as of Oct 23, 2026: a share price of $13.75 against $0.77 of earnings per share over the last twelve months.

That is above its 5-year median of 5.9×, higher than on 97% of days in the last 5 years.

Over that time it ranged from 2.5× in Oct 2025 to 18.7× in May 2026.

The median for 10 large drugmakers of a similar size is 31.5×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.9×	3.8×	18.7×
2025	3.7×	2.5×	4.6×
2024	3.0×	2.9×	8.2×
2023	6.3×	4.8×	8.1×
2022	7.1×	5.4×	7.6×

Against its peers

Companies in Drug Manufacturers - General nearest Organon's size, closest first, today.

Company	PE ratio
OGNOrganon	17.9×
LQDALiquidia	30.7×
ARQTArcutis Biotherapeutics	142×
INDVIndivior Pharmaceuticals	12.4×
NRIXNurix Therapeutics	11.0×
PBHPrestige Consumer Healthcare	13.4×
KNSAKiniksa Pharmaceuticals International	79.1×
LGNDLigand Pharmaceuticals	32.3×
HRMYHarmony Biosciences	11.7×
AMRXAmneal Pharmaceuticals	41.6×
ALKSAlkermes plc.	115×
Peer median	31.5×

Where Organon ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Organon

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.